多基站可充电无线传感器网络建模及优化研究

研究问题为引入无线能量补给设备后,多基站无线传感器网络的跨层优化问题。以设计无线传感器网络中的数据路由、传感器节点的功率控制及无线能量补给设备的工作策略为研究目标,通过提出无线传感器网络中传感器节点活跃度的概念,分析无线传感器网络物理层与网络层需要满足的约束条件,结合无线能量补给设备需要满足的约束条件,提出可充电无线传感器动态网络跨层优化问题,并将其转化为易于求解的线性规划问题。根据求得的最优解获得无线传感器网络中传感器节点动态且周期的数据路由及功率控制策略,并得到无线能量补给设备周期性工作策略,且无线能量补给设备驻站时间比较之前研究成果提升在100%以上。     

In vitro cytocompatibility and corrosion resistance of zinc-doped hydroxyapatite coatings on a titanium substrate

To improve biocompatibility and corrosion resistance during the initial implantation stage, zinc-substituted hydroxyapatite (ZnHAp) coating was fabricated on pure titanium by the electrolytic deposition method. The morphology, microstructure and chemical composition of the coating were investigated by X-ray diffraction, scanning electron microscopy, energy-dispersive X-ray analysis and Fourier transform infrared spectroscopy. The prepared ZnHAp crystals were calcium deficient and were carbonated owing to the incorporation of some Zn²⁺. This incorporation of Zn²⁺ into the HAp significantly reduced porosity and caused the coating to become noticeably denser. In addition, the Zn²⁺ ions were homogeneously distributed in the coating. The potentiodynamic polarisation test revealed that the ZnHAp-coated surface showed superior corrosion resistance over that of the HAp-coated surface and bare Ti. The in vitro bioactivity was evaluated in a simulated body fluid, which revealed that the ZnHAp coating can rapidly induce bone-like apatite formation of nuclear and growth features. In addition, the cell response tests showed that the MC3T3-E1 cells on the ZnHAp coating clearly enhanced the in vitro cytocompatibility of Ti compared with the same cells on HAp coating. ZnHAp coating was thus beneficial for improving biocompatibility.     

Pharmacokinetic interaction study of combining imatinib with dasatinib in rats by UPLC–MS/MS

Abstract

This study examined whether oral administration of dasatinib to the rats with imatinib led to any pharmacokinetic interactions. Twenty-four rats were divided randomly into three groups, imatinib group (imatinib 25?mg/kg, n?=?8), dasatinib group (dasatinib 15?mg/kg, n?=?8) and co-administration group (dasatinib 15?mg/kg and imatinib 25?mg/kg, n?=?8). The concentration of imatinib and dasatinib in rat plasma was determined by a sensitive and simple UPLC–MS/MS method. There was statistical pharmacokinetics difference for imatinib in the imatinib group and co-administration group, when co-oral administration imatinib with dasatinib, MRT_(0–t) increased (p?<?0.01). There was statistical pharmacokinetics difference for dasatinib in the dasatinib group and co-administration group, when co-oral administration dasatinib with imatinib, C_max and AUC increased (p?<?0.01), CL and V decreased (p?<?0.01). These data indicate dasatinib could slightly influence the pharmacokinetic profile of imatinib in rats, and imatinib could influence the pharmacokinetic profile of dasatinib in rats, which might cause drug–drug interactions when using imatinib with dasatinib.